SPY382.88-1.36 -0.35%
DIA309.97-1.90 -0.61%
IXIC13,543.06+12.15 0.09%

Oppenheimer Downgrades Biohaven Pharmaceutical to Perform, Lowers Price Target to $51

Oppenheimer analyst Esther Rajavelu downgrades Biohaven Pharmaceutical (NYSE:BHVN) from Outperform to Perform and lowers the price target from $67 to $51.

Benzinga · 02/10/2020 15:19

Oppenheimer analyst Esther Rajavelu downgrades Biohaven Pharmaceutical (NYSE:BHVN) from Outperform to Perform and lowers the price target from $67 to $51.